Publications by authors named "June Almenoff"

Claim this Profile
P
Physiologically Based Pharmacokinetic Modeling and Simulation to Support a Change in the FDA-Labeled Dosing Frequency of RHB-105 Low-Dose Rifabutin Triple Therapy for Helicobacter pylori Eradication.
Nimish Vakil, Colin W Howden, Shailja C Shah, Kuan-Fu Chen, Elliot Offman, June S Almenoff

J Clin Pharmacol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a new travellers' diarrhoea clinical severity classification and its utility in confirming rifamycin-SV efficacy.
Herbert L DuPont, June S Almenoff, Mansi S Jamindar, Enoch Bortey, Robert Steffen

J Travel Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Vonoprazan- and Rifabutin-Based Regimens.
June Almenoff

Am J Gastroenterol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Naloxegol in Patients with Chronic Non-Cancer Pain Who Experience Opioid-Induced Constipation: A Pooled Analysis of Two Global, Randomized Controlled Studies.
William D Chey, Darren M Brenner, Brooks D Cash, Martin Hale, Jeremy Adler, June S Almenoff

J Pain Res· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically-based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infection.
Colin W Howden, Shailja Shah, Salil N Pendse, Elliot Offman, June S Almenoff

Aliment Pharmacol Ther· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data.
Colin W Howden, Kely L Sheldon, June S Almenoff, William D Chey

Dig Dis Sci· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia.
Paul S Covington, J Michael Davenport, David A Andrae, Martin E Stryjewski, Lisa L Turner, June Almenoff

J Antimicrob Chemother· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Leonard S Dove, Anthony Lembo, Charles W Randall, Ronald Fogel, David Andrae, June S Almenoff

Gastroenterology· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Summary of Pharmacokinetics and Tissue Distribution of a Broad-Spectrum Fluoroquinolone, JNJ-Q2.
J Michael Davenport, Paul Covington, Mark Gotfried, Matthew Medlock, Prapoch Watanalumlerd, June Almenoff

Clin Pharmacol Drug Dev· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection.
Paul Covington, J Michael Davenport, David Andrae, William O'Riordan, Lisa Liverman, June Almenoff

Antimicrob Agents Chemother· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
Dana E Vanderwall, Nancy Yuen, Mohammad Al-Ansari, James Bailey, David Fram, June S Almenoff

Drug Discov Today· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innovations for the future of pharmacovigilance.
June S Almenoff

Drug Saf· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
June S Almenoff, Karol K LaCroix, Nancy A Yuen, David Fram, William DuMouchel

Drug Saf· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolving paradigms in pharmacovigilance.
Wendy Brewster, Trevor Gibbs, Karol Lacroix, Alison Murray, Michael Tydeman, June Almenoff

Curr Drug Saf· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives on the use of data mining in pharmaco-vigilance.
June Almenoff, Joseph M Tonning, A Lawrence Gould, Ana Szarfman, Manfred Hauben

Drug Saf· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data.
William DuMouchel, Eric T Smith, Richard Beasley, Harold Nelson, Xionghu Yang, June S Almenoff

Clin Ther· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting.
June S Almenoff, William DuMouchel, L Allen Kindman, Xionghu Yang, David Fram

Pharmacoepidemiol Drug Saf· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis